Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial
Circulation · 23.06.2026 · 153 (25) · 1973-1983
DOI: 10.1161/circulationaha.126.080833 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 23.06.2026. Verfasst von Sebastiaan Dhont und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium (S.D., P.M., E.M., S.D., W.M., P.B.B.). Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Failure, Stroke Volume, Neprilysin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: FWO.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsartan reduces functional mitral regurgitation (MR) in HF with reduced EF (HFrEF), its impact on exercise hemodynamics and the dynamic burden of AFMR in HFpEF remains to be elucidated. METHODS: This multicenter, randomized, open-label trial with blinded primary endpoint assessment assigned 84 patients with symptomatic HFpEF and at least moderate AFMR within the previous year to sacubitril/valsartan (n=41) or standard-of-care (SOC; n=43). The primary outcome was the 6-month change in the exercise mean pulmonary arterial pressure to cardiac output (mPAP/CO) slope, assessed using cardiopulmonary exercise testing with simultaneous echocardiography (CPETecho). Secondary outcomes included changes in peak oxygen consumption (peak VO 2 ), Kansas City Cardiomyopathy Questionnaire (KCCQ), N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, left atrial (LA) volume and function, and AFMR severity in rest and during stress. RESULTS: At 6 months, sacubitril/valsartan significantly improved the mPAP/CO slope compared with SOC (adjusted between-group difference in change, –0.93 mm Hg/L/min; 95% CI, –1.80 to –0.07; P =0.035). This hemodynamic benefit was accompanied by improvements in peak VO 2 (mean change, +0.9 versus –0.6mL/kg/min; P =0.002) and KCCQ (median increase, 10 versus 2 points; P =0.002). Significant reductions in NT-proBNP and LA volume were observed ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium (S.D., P.M., E.M., S.D., W.M., P.B.B.).
- Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (S.D., S.M.F., P.K., E.M., K.T., S.D., L.H., W.M., J.V., P.B.B.).
- Department of Cardiology, Jessa & Science, Jessa Hospital, Hasselt, Belgium (S.M.F, L.H., J.V.).
- Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Jette, Belgium (X.G., F.H.V.).
- Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium (X.G., F.H.V.).
ORCID-Profile: Sebastiaan Dhont, Sara Moura Ferreira, Xavier Galloo, Pieter Martens, Evelyne Meekers, Sébastien Deferm, Lieven Herbots, Wilfried Mullens, Frederik H Verbrugge, Jan Verwerft, Philippe B Bertrand
Förderung
- FWO
Zitieren
APA
Dhont, S., Moura Ferreira, S., Galloo, X., Martens, P., Meekers, E., Tartaglia, K., Deferm, S., Herbots, L., Mullens, W., Verbrugge, F. H., Verwerft, J., & Bertrand, P. B. (2026). Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial. Circulation, 153(25), 1973-1983. https://doi.org/10.1161/circulationaha.126.080833
Vancouver
Dhont S, Moura Ferreira S, Galloo X, Martens P, Meekers E, Tartaglia K, et al. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial. Circulation. 2026;153(25):1973-1983. doi:10.1161/circulationaha.126.080833
BibTeX
@article{Dhont2026,
author = {Dhont, Sebastiaan and Moura Ferreira, Sara and Galloo, Xavier and Martens, Pieter and Meekers, Evelyne and Tartaglia, Katrien and Deferm, Sébastien and Herbots, Lieven and Mullens, Wilfried and Verbrugge, Frederik H and Verwerft, Jan and Bertrand, Philippe B},
title = {Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial},
journal = {Circulation},
year = {2026},
volume = {153},
number = {25},
pages = {1973--1983},
doi = {10.1161/circulationaha.126.080833}
}
EUVIMED